Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 173

1.

PROPERTIES AND FUNCTIONS OF THE NOVEL TYPE I INTERFERON EPSILON.

Marks ZRC, Campbell N, deWeerd NA, Lim SS, Gearing LJ, Bourke NM, Hertzog PJ.

Semin Immunol. 2019 Jun;43:101328. doi: 10.1016/j.smim.2019.101328. Epub 2019 Nov 14. Review.

PMID:
31734130
2.

CiiiDER: A tool for predicting and analysing transcription factor binding sites.

Gearing LJ, Cumming HE, Chapman R, Finkel AM, Woodhouse IB, Luu K, Gould JA, Forster SC, Hertzog PJ.

PLoS One. 2019 Sep 4;14(9):e0215495. doi: 10.1371/journal.pone.0215495. eCollection 2019.

3.

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, Toole SO, Ganju V, Parker BS.

NPJ Precis Oncol. 2019 Aug 29;3:21. doi: 10.1038/s41698-019-0093-2. eCollection 2019.

4.

Early T-BET Expression Ensures an Appropriate CD8+ Lineage-Specific Transcriptional Landscape after Influenza A Virus Infection.

Prier JE, Li J, Gearing LJ, Olshansky M, Sng XYX, Hertzog PJ, Turner SJ.

J Immunol. 2019 Aug 15;203(4):1044-1054. doi: 10.4049/jimmunol.1801431. Epub 2019 Jun 21.

PMID:
31227580
5.

A structural "star" in interferon gamma signaling.

Hertzog PJ, de Weerd NA.

Immunol Cell Biol. 2019 May;97(5):442-444. doi: 10.1111/imcb.12255. No abstract available.

PMID:
31131497
6.

A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis.

Severa M, Rizzo F, Srinivasan S, Di Dario M, Giacomini E, Buscarinu MC, Cruciani M, Etna MP, Sandini S, Mechelli R, Farina A, Trivedi P, Hertzog PJ, Salvetti M, Farina C, Coccia EM.

J Autoimmun. 2019 Jul;101:1-16. doi: 10.1016/j.jaut.2019.04.006. Epub 2019 Apr 30.

PMID:
31047767
7.

A subset of HLA-I peptides are not genomically templated: Evidence for cis- and trans-spliced peptide ligands.

Faridi P, Li C, Ramarathinam SH, Vivian JP, Illing PT, Mifsud NA, Ayala R, Song J, Gearing LJ, Hertzog PJ, Ternette N, Rossjohn J, Croft NP, Purcell AW.

Sci Immunol. 2018 Oct 12;3(28). pii: eaar3947. doi: 10.1126/sciimmunol.aar3947.

PMID:
30315122
8.

Plasmacytoid dendritic cell heterogeneity is defined by CXCL10 expression following TLR7 stimulation.

Marsman C, Lafouresse F, Liao Y, Baldwin TM, Mielke LA, Hu Y, Mack M, Hertzog PJ, de Graaf CA, Shi W, Groom JR.

Immunol Cell Biol. 2018 Nov;96(10):1083-1094. doi: 10.1111/imcb.12173. Epub 2018 Jun 25.

PMID:
29870118
9.

A proline deletion in IFNAR1 impairs IFN-signaling and underlies increased resistance to tuberculosis in humans.

Zhang G, deWeerd NA, Stifter SA, Liu L, Zhou B, Wang W, Zhou Y, Ying B, Hu X, Matthews AY, Ellis M, Triccas JA, Hertzog PJ, Britton WJ, Chen X, Feng CG.

Nat Commun. 2018 Jan 8;9(1):85. doi: 10.1038/s41467-017-02611-z.

10.

Regulation of H3K4me3 at Transcriptional Enhancers Characterizes Acquisition of Virus-Specific CD8+ T Cell-Lineage-Specific Function.

Russ BE, Olshansky M, Li J, Nguyen MLT, Gearing LJ, Nguyen THO, Olson MR, McQuilton HA, Nüssing S, Khoury G, Purcell DFJ, Hertzog PJ, Rao S, Turner SJ.

Cell Rep. 2017 Dec 19;21(12):3624-3636. doi: 10.1016/j.celrep.2017.11.097.

11.

Defining the distinct, intrinsic properties of the novel type I interferon, IFNϵ.

Stifter SA, Matthews AY, Mangan NE, Fung KY, Drew A, Tate MD, Soares da Costa TP, Hampsey D, Mayall J, Hansbro PM, Garcia Minambres A, Eid SG, Mak J, Scoble J, Lovrecz G, deWeerd NA, Hertzog PJ.

J Biol Chem. 2018 Mar 2;293(9):3168-3179. doi: 10.1074/jbc.M117.800755. Epub 2017 Nov 29.

12.

Type-I interferon signalling through IFNAR1 plays a deleterious role in the outcome after stroke.

Zhang M, Downes CE, Wong CHY, Brody KM, Guio-Agulair PL, Gould J, Ates R, Hertzog PJ, Taylor JM, Crack PJ.

Neurochem Int. 2017 Sep;108:472-480. doi: 10.1016/j.neuint.2017.06.009. Epub 2017 Jun 22.

PMID:
28647375
13.

A hot spot on interferon α/β receptor subunit 1 (IFNAR1) underpins its interaction with interferon-β and dictates signaling.

de Weerd NA, Matthews AY, Pattie PR, Bourke NM, Lim SS, Vivian JP, Rossjohn J, Hertzog PJ.

J Biol Chem. 2017 May 5;292(18):7554-7565. doi: 10.1074/jbc.M116.773788. Epub 2017 Mar 13.

14.

RNA-Seq analysis of chikungunya virus infection and identification of granzyme A as a major promoter of arthritic inflammation.

Wilson JA, Prow NA, Schroder WA, Ellis JJ, Cumming HE, Gearing LJ, Poo YS, Taylor A, Hertzog PJ, Di Giallonardo F, Hueston L, Le Grand R, Tang B, Le TT, Gardner J, Mahalingam S, Roques P, Bird PI, Suhrbier A.

PLoS Pathog. 2017 Feb 16;13(2):e1006155. doi: 10.1371/journal.ppat.1006155. eCollection 2017 Feb.

15.

Interferon epsilon promotes HIV restriction at multiple steps of viral replication.

Garcia-Minambres A, Eid SG, Mangan NE, Pade C, Lim SS, Matthews AY, de Weerd NA, Hertzog PJ, Mak J.

Immunol Cell Biol. 2017 May;95(5):478-483. doi: 10.1038/icb.2016.123. Epub 2017 Jan 3.

PMID:
28045025
16.

IFNAR1-Signalling Obstructs ICOS-mediated Humoral Immunity during Non-lethal Blood-Stage Plasmodium Infection.

Sebina I, James KR, Soon MS, Fogg LG, Best SE, Labastida Rivera F, Montes de Oca M, Amante FH, Thomas BS, Beattie L, Souza-Fonseca-Guimaraes F, Smyth MJ, Hertzog PJ, Hill GR, Hutloff A, Engwerda CR, Haque A.

PLoS Pathog. 2016 Nov 3;12(11):e1005999. doi: 10.1371/journal.ppat.1005999. eCollection 2016 Nov.

17.

Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition.

Tate MD, Ong JDH, Dowling JK, McAuley JL, Robertson AB, Latz E, Drummond GR, Cooper MA, Hertzog PJ, Mansell A.

Sci Rep. 2016 Jun 10;6:27912. doi: 10.1038/srep27912.

18.

Antitumour actions of interferons: implications for cancer therapy.

Parker BS, Rautela J, Hertzog PJ.

Nat Rev Cancer. 2016 Mar;16(3):131-44. doi: 10.1038/nrc.2016.14. Review.

PMID:
26911188
19.

Blocking HIV-1 transmission in the female reproductive tract: from microbicide development to exploring local antiviral responses.

Eid SG, Mangan NE, Hertzog PJ, Mak J.

Clin Transl Immunology. 2015 Oct 9;4(10):e43. doi: 10.1038/cti.2015.23. eCollection 2015 Oct. Review.

20.

MicroRNA as Type I Interferon-Regulated Transcripts and Modulators of the Innate Immune Response.

Forster SC, Tate MD, Hertzog PJ.

Front Immunol. 2015 Jul 8;6:334. doi: 10.3389/fimmu.2015.00334. eCollection 2015. Review.

21.

Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer.

Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, Lucas EC, Hawkins ED, Lock P, Wong CS, Chen W, Anderson RL, Hertzog PJ, Andrews DM, Möller A, Parker BS.

Cancer Immunol Res. 2015 Nov;3(11):1207-17. doi: 10.1158/2326-6066.CIR-15-0065. Epub 2015 Jul 21.

22.

Dynamic control of type I IFN signalling by an integrated network of negative regulators.

Porritt RA, Hertzog PJ.

Trends Immunol. 2015 Mar;36(3):150-60. doi: 10.1016/j.it.2015.02.002. Epub 2015 Feb 25. Review.

PMID:
25725583
23.

Glucocorticosteroids enhance replication of respiratory viruses: effect of adjuvant interferon.

Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD.

Sci Rep. 2014 Nov 24;4:7176. doi: 10.1038/srep07176.

24.

Spatiotemporal requirements for IRF7 in mediating type I IFN-dependent susceptibility to blood-stage Plasmodium infection.

Edwards CL, Best SE, Gun SY, Claser C, James KR, de Oca MM, Sebina I, Rivera Fde L, Amante FH, Hertzog PJ, Engwerda CR, Renia L, Haque A.

Eur J Immunol. 2015 Jan;45(1):130-41. doi: 10.1002/eji.201444824. Epub 2014 Nov 13.

25.

Type I IFN signaling in CD8- DCs impairs Th1-dependent malaria immunity.

Haque A, Best SE, Montes de Oca M, James KR, Ammerdorffer A, Edwards CL, de Labastida Rivera F, Amante FH, Bunn PT, Sheel M, Sebina I, Koyama M, Varelias A, Hertzog PJ, Kalinke U, Gun SY, Rénia L, Ruedl C, MacDonald KP, Hill GR, Engwerda CR.

J Clin Invest. 2014 Jun;124(6):2483-96. doi: 10.1172/JCI70698. Epub 2014 May 1.

26.

Soluble IFN receptor potentiates in vivo type I IFN signaling and exacerbates TLR4-mediated septic shock.

Samarajiwa SA, Mangan NE, Hardy MP, Najdovska M, Dubach D, Braniff SJ, Owczarek CM, Hertzog PJ.

J Immunol. 2014 May 1;192(9):4425-35. doi: 10.4049/jimmunol.1302388. Epub 2014 Apr 2.

27.

The role of Ets2 transcription factor in the induction of microRNA-155 (miR-155) by lipopolysaccharide and its targeting by interleukin-10.

Quinn SR, Mangan NE, Caffrey BE, Gantier MP, Williams BR, Hertzog PJ, McCoy CE, O'Neill LA.

J Biol Chem. 2014 Feb 14;289(7):4316-25. doi: 10.1074/jbc.M113.522730. Epub 2013 Dec 20.

28.

In vivo comparison of local versus systemic delivery of immunostimulating siRNA in HPV-driven tumours.

Khairuddin N, Blake SJ, Firdaus F, Steptoe RJ, Behlke MA, Hertzog PJ, McMillan NA.

Immunol Cell Biol. 2014 Feb;92(2):156-63. doi: 10.1038/icb.2013.75. Epub 2013 Nov 12.

PMID:
24217808
29.

Purification and biological characterization of soluble, recombinant mouse IFNβ expressed in insect cells.

Stifter SA, Gould JA, Mangan NE, Reid HH, Rossjohn J, Hertzog PJ, de Weerd NA.

Protein Expr Purif. 2014 Feb;94:7-14. doi: 10.1016/j.pep.2013.10.019. Epub 2013 Nov 6.

PMID:
24211771
30.

Non-essential role for TLR2 and its signaling adaptor Mal/TIRAP in preserving normal lung architecture in mice.

Ruwanpura SM, McLeod L, Lilja AR, Brooks G, Dousha LF, Seow HJ, Bozinovski S, Vlahos R, Hertzog PJ, Anderson GP, Jenkins BJ.

PLoS One. 2013 Oct 29;8(10):e78095. doi: 10.1371/journal.pone.0078095. eCollection 2013.

31.

The early monocytic response to cytomegalovirus infection is MyD88 dependent but occurs independently of common inflammatory cytokine signals.

Wikstrom ME, Khong A, Fleming P, Kuns R, Hertzog PJ, Frazer IH, Andoniou CE, Hill GR, Degli-Esposti MA.

Eur J Immunol. 2014 Feb;44(2):409-19. doi: 10.1002/eji.201243109. Epub 2013 Dec 16.

32.

Structural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1.

de Weerd NA, Vivian JP, Nguyen TK, Mangan NE, Gould JA, Braniff SJ, Zaker-Tabrizi L, Fung KY, Forster SC, Beddoe T, Reid HH, Rossjohn J, Hertzog PJ.

Nat Immunol. 2013 Sep;14(9):901-7. doi: 10.1038/ni.2667. Epub 2013 Jul 21.

PMID:
23872679
33.

Fine tuning type I interferon responses.

Hertzog PJ, Williams BR.

Cytokine Growth Factor Rev. 2013 Jun;24(3):217-25. doi: 10.1016/j.cytogfr.2013.04.002. Epub 2013 May 25. Review.

PMID:
23711406
34.

Overview of cytokine and growth factor review focus on Australia. Preface.

Hertzog PJ, Mangan NE.

Cytokine Growth Factor Rev. 2013 Jun;24(3):175-7. doi: 10.1016/j.cytogfr.2013.04.004. Epub 2013 May 18. No abstract available.

PMID:
23688652
35.

CpG pretreatment enhances antiviral T-cell immunity against cytomegalovirus.

Ong ML, Wikstrom ME, Fleming P, Estcourt MJ, Hertzog PJ, Hill GR, Andoniou CE, Degli-Esposti MA.

Blood. 2013 Jul 4;122(1):55-60. doi: 10.1182/blood-2012-12-471227. Epub 2013 May 14.

36.

The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone.

Slaney CY, Möller A, Hertzog PJ, Parker BS.

Oncoimmunology. 2013 Jan 1;2(1):e22339.

37.

Interferon-ε protects the female reproductive tract from viral and bacterial infection.

Fung KY, Mangan NE, Cumming H, Horvat JC, Mayall JR, Stifter SA, De Weerd N, Roisman LC, Rossjohn J, Robertson SA, Schjenken JE, Parker B, Gargett CE, Nguyen HP, Carr DJ, Hansbro PM, Hertzog PJ.

Science. 2013 Mar 1;339(6123):1088-92. doi: 10.1126/science.1233321.

38.

Mitochondrially localised MUL1 is a novel modulator of antiviral signaling.

Jenkins K, Khoo JJ, Sadler A, Piganis R, Wang D, Borg NA, Hjerrild K, Gould J, Thomas BJ, Nagley P, Hertzog PJ, Mansell A.

Immunol Cell Biol. 2013 Apr;91(4):321-30. doi: 10.1038/icb.2013.7. Epub 2013 Feb 12.

PMID:
23399697
39.

RNA-eXpress annotates novel transcript features in RNA-seq data.

Forster SC, Finkel AM, Gould JA, Hertzog PJ.

Bioinformatics. 2013 Mar 15;29(6):810-2. doi: 10.1093/bioinformatics/btt034. Epub 2013 Feb 8.

40.

Interferome v2.0: an updated database of annotated interferon-regulated genes.

Rusinova I, Forster S, Yu S, Kannan A, Masse M, Cumming H, Chapman R, Hertzog PJ.

Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6. doi: 10.1093/nar/gks1215. Epub 2012 Nov 29.

41.

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.

Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Möller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS.

Nat Med. 2012 Aug;18(8):1224-31. doi: 10.1038/nm.2830. Epub 2012 Jul 22.

PMID:
22820642
42.

Overview. Type I interferons as primers, activators and inhibitors of innate and adaptive immune responses.

Hertzog PJ.

Immunol Cell Biol. 2012 May;90(5):471-3. doi: 10.1038/icb.2012.15. No abstract available.

PMID:
22648073
43.

Interferons as biomarkers and effectors: lessons learned from animal models.

Berry CM, Hertzog PJ, Mangan NE.

Biomark Med. 2012 Apr;6(2):159-76. doi: 10.2217/BMM.12.10. Review.

PMID:
22448790
44.

The Ets transcription factor ELF5 functions as a tumor suppressor in the kidney.

Lapinskas EJ, Svobodova S, Davis ID, Cebon J, Hertzog PJ, Pritchard MA.

Twin Res Hum Genet. 2011 Aug;14(4):316-22. doi: 10.1375/twin.14.4.316.

PMID:
21787113
45.

Suppressor of cytokine signaling (SOCS) 1 inhibits type I interferon (IFN) signaling via the interferon alpha receptor (IFNAR1)-associated tyrosine kinase Tyk2.

Piganis RA, De Weerd NA, Gould JA, Schindler CW, Mansell A, Nicholson SE, Hertzog PJ.

J Biol Chem. 2011 Sep 30;286(39):33811-8. doi: 10.1074/jbc.M111.270207. Epub 2011 Jul 13.

46.

Type I-IFNs control GVHD and GVL responses after transplantation.

Robb RJ, Kreijveld E, Kuns RD, Wilson YA, Olver SD, Don AL, Raffelt NC, De Weerd NA, Lineburg KE, Varelias A, Markey KA, Koyama M, Clouston AD, Hertzog PJ, Macdonald KP, Hill GR.

Blood. 2011 Sep 22;118(12):3399-409. doi: 10.1182/blood-2010-12-325746. Epub 2011 Jun 30.

PMID:
21719602
47.

Sculpting the immune response to infection.

Hertzog PJ, Mansell A, van Driel IR, Hartland EL.

Nat Immunol. 2011 Jun 20;12(7):579-82. doi: 10.1038/ni0711-579. No abstract available.

PMID:
21685948
48.

LPS hypersensitivity of gp130 mutant mice is independent of elevated haemopoietic TLR4 signaling.

Greenhill CJ, Gould J, Ernst M, Jarnicki A, Hertzog PJ, Mansell A, Jenkins BJ.

Immunol Cell Biol. 2012 May;90(5):559-63. doi: 10.1038/icb.2011.56. Epub 2011 Jun 14. Erratum in: Immunol Cell Biol. 2012 May;90(5):564. Jarnicki, Andrew [added].

PMID:
21670738
49.

Analysis of microRNA turnover in mammalian cells following Dicer1 ablation.

Gantier MP, McCoy CE, Rusinova I, Saulep D, Wang D, Xu D, Irving AT, Behlke MA, Hertzog PJ, Mackay F, Williams BR.

Nucleic Acids Res. 2011 Jul;39(13):5692-703. doi: 10.1093/nar/gkr148. Epub 2011 Mar 29.

50.

Macrophage activation and differentiation signals regulate schlafen-4 gene expression: evidence for Schlafen-4 as a modulator of myelopoiesis.

van Zuylen WJ, Garceau V, Idris A, Schroder K, Irvine KM, Lattin JE, Ovchinnikov DA, Perkins AC, Cook AD, Hamilton JA, Hertzog PJ, Stacey KJ, Kellie S, Hume DA, Sweet MJ.

PLoS One. 2011 Jan 7;6(1):e15723. doi: 10.1371/journal.pone.0015723.

Supplemental Content

Loading ...
Support Center